NLRP3 and systemic lupus erythematosus: Therapeutic potentials of several NLRP3 targeting miRNAs were investigated in autoimmune diseases such as inflammatory bowel diseases (IBDs) (Neudecker et al., 2017), RA (Xie Z. et al., 2018), type 1 diabetes (T1D) (Yang and Chiang, 2015), type 2 diabetes (T2D) (Yang and Chiang, 2015), and systemic lupus erythematosus (SLE) (Zhu et al., 2012).